You just read:

Imprimis Pharmaceuticals Announces New Economic Study Demonstrating $8.7 Billion in Potential Cost Savings over the Next 10 Years with the Adoption of Dropless Therapy™

News provided by

Imprimis Pharmaceuticals, Inc.

Oct 26, 2015, 08:45 ET